Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06173726 |
Recruitment Status :
Not yet recruiting
First Posted : December 18, 2023
Last Update Posted : December 18, 2023
|
Sponsor:
BioSyngen Pte Ltd
Collaborator:
Shenzhen Second People's Hospital
Information provided by (Responsible Party):
BioSyngen Pte Ltd
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Not yet recruiting |
---|---|
Estimated Primary Completion Date : | December 5, 2026 |
Estimated Study Completion Date : | December 5, 2026 |